News

HDA UK Media And Political Bulletin – 5 March 2018

Media and Political Bulletin

5 March 2018

Media Summary

The pharmaceutical industry response to the Prime Minister’s ‘Road to Brexit’ speech

ABPI, 2 March 2018

 

The ABPI has responded to the ‘Road to Brexit’ speech by Prime Minister Theresa May on 2 March. In the speech the Prime Minister outlined that “UK and EU regulatory standards will remain substantially similar in the future” and that “membership of the European Medicines Agency would mean investment in new innovative medicines continuing in the UK”.

Reacting to the speech, Chief Executive of the ABPI, Mike Thompson said:

“Every month, 45 million packs of medicines move from the UK to the EU – and 37 million come the other way. That is why the Prime Minister’s commitment to seek cooperation on medicines regulation would be the best outcome for patients, not just in the UK but across Europe.

“It’s now critical that both sides prioritise patient safety in phase two of the negotiations. Delivering close cooperation on the regulation of medicines is only one part of the challenge. Making sure the supply of medicines is uninterrupted is essential to ensure patients in the UK and EU can get the medicines they need from day one of Brexit.”

 

Parliamentary Coverage

 

There is no parliamentary coverage today.

 

Full Coverage

The pharmaceutical industry response to the Prime Minister’s ‘Road to Brexit’ speech

ABPI, 2 March 2018

In today’s speech, the Prime Minister outlined that “UK and EU regulatory standards will remain substantially similar in the future” and that “membership of the European Medicines Agency would mean investment in new innovative medicines continuing in the UK”.

Reacting to the speech, Chief Executive of the ABPI, Mike Thompson said:

“Every month, 45 million packs of medicines move from the UK to the EU – and 37 million come the other way. That is why the Prime Minister’s commitment to seek cooperation on medicines regulation would be the best outcome for patients, not just in the UK but across Europe.

“It’s now critical that both sides prioritise patient safety in phase two of the negotiations. Delivering close cooperation on the regulation of medicines is only one part of the challenge. Making sure the supply of medicines is uninterrupted is essential to ensure patients in the UK and EU can get the medicines they need from day one of Brexit.”

The pharmaceutical industry’s policy priorities for Brexit are:

Securing a transition period. This should be a single-step transition that adequately reflects the time needed by pharmaceutical companies to transition to a new framework.

Securing co-operation with the EU on the regulation of medicines. This should achieve alignment between the UK and EU regulatory framework, to deliver proportionate, robust and effective regulation of medicines in the UK.

Securing the ability to freely trade and move medicines and pharmaceutical supplies across borders. This should be ‘frictionless’ and include access to free trade agreements already in place between third countries and the EU.

Securing access to the best talent. This should achieve an immigration system which allows global pharmaceutical companies to attract and transfer talented and skilled students, scientists and other professionals from around the world.

Securing predictable access to funding and collaboration for scientific research. This should achieve agreements on existing and future funding and collaboration opportunities such as Horizon 2020 (and its successor), including the Innovative Medicines Initiative. UK life science entrepreneurs should also be able to access the European Investment Bank and European Investment Fund.

HDA UK Media And Political Bulletin – 5 March 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?